Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics

Avadel Pharma enters into royalty agreement with RTW investments for up to $75M

• Avadel Pharmaceuticals (NASDAQ:AVDL) on Wednesday said it had entered into a royalty agreement to support the potential commercialization of its sleep disorder drug Lumryz.
• The company said it had entered into a deal with RTW Investments and certain of its affiliates for up to $75M.
• AVDL is developing Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
• The company also said that, concurrently, it had extended the maturity of $96.2M of its convertible notes to 2027.
• “These critical financing activities, including ...

  Seeking Alpha | March 29, 2023

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”). Each ADS represents the right to receive one Ordinary Share. Avadel may, in lieu of ADSs, offer and sell to certain

Yahoo | March 29, 2023

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its entry into a royalty agreement with RTW Investments, LP and certain of its affiliates (“RTW”) for up

Yahoo | March 29, 2023

Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approval decisionDUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ. Through its PLAIR, Avadel is authorized to import unapproved drug

Yahoo | March 22, 2023

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one (1) new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance wit

Yahoo | March 21, 2023